Mihaela Rata1, Nandita Desouza1, Michael Germuska1, Michael Partridge2, Martin O. Leach1, Geoffrey S. Payne1
1MRI Unit, CR-UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; 2Radiotherapy and Imaging, CR-UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom
18FDG PET uptake represents the gold standard technique for staging aggressive non-Hodgkins lymphomas (NHL) but quantified SUVmax at outset is also predictive of treatment response. The phosphomonester peak normalized by the total amount of -NTP (nucleoside triphosphates) on 31P-MRS has also demonstrated promise as a predictive biomarker: This study explores the relationship between the predictive biomarkers. The absence of significant correlation between the glucose uptake using 18FDG-PET and PME/bNTP using 31P MRS suggests that they may contain complementary information on response prediction